The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

S. M. Keller; M. G. Vangel; S. Adak; H. Wagner; J. H. Schiller; A. Herskovic; R. Komaki; M. C. Perry; R. S. Marks; R. B. Livingston; D. H. Johnson

doi:10.1016/S0169-5002(02)00103-4

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

S. M. Keller, M. G. Vangel, S. Adak, H. Wagner, J. H. Schiller, A. Herskovic, R. Komaki, M. C. Perry, R. S. Marks, R. B. Livingston, D. H. Johnson

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

Original language	English (US)
Pages (from-to)	303-309
Number of pages	7
Journal	Lung Cancer
Volume	37
Issue number	3
DOIs	https://doi.org/10.1016/S0169-5002(02)00103-4
State	Published - Sep 2002

Keywords

Adjuvant therapy
Gender
Non-small cell lung cancer

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/S0169-5002(02)00103-4

Cite this

Keller, S. M., Vangel, M. G., Adak, S., Wagner, H., Schiller, J. H., Herskovic, A., Komaki, R., Perry, M. C., Marks, R. S., Livingston, R. B., & Johnson, D. H. (2002). The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer, 37(3), 303-309. https://doi.org/10.1016/S0169-5002(02)00103-4

Keller, SM, Vangel, MG, Adak, S, Wagner, H, Schiller, JH, Herskovic, A, Komaki, R, Perry, MC, Marks, RS, Livingston, RB & Johnson, DH 2002, 'The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer', Lung Cancer, vol. 37, no. 3, pp. 303-309. https://doi.org/10.1016/S0169-5002(02)00103-4

@article{2463aa9f6d0c4696892406723893dc57,

title = "The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer",

abstract = "This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.",

keywords = "Adjuvant therapy, Gender, Non-small cell lung cancer",

author = "Keller, {S. M.} and Vangel, {M. G.} and S. Adak and H. Wagner and Schiller, {J. H.} and A. Herskovic and R. Komaki and Perry, {M. C.} and Marks, {R. S.} and Livingston, {R. B.} and Johnson, {D. H.}",

note = "Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair); participating cooperative groups included the Cancer and Leukemia Group B, the North Central Cancer Treatment Group, the Radiation Therapy Oncology Group, and the Southwest Oncology Group. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Supported in part by grants from the Public Health Service (CA23318, CA66636, CA21115, CA14958, CA49957, CA21076, CA73590, CA25224, CA21661, CA20319), the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.",

year = "2002",

month = sep,

doi = "10.1016/S0169-5002(02)00103-4",

language = "English (US)",

volume = "37",

pages = "303--309",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

AU - Keller, S. M.

AU - Vangel, M. G.

AU - Adak, S.

AU - Wagner, H.

AU - Schiller, J. H.

AU - Herskovic, A.

AU - Komaki, R.

AU - Perry, M. C.

AU - Marks, R. S.

AU - Livingston, R. B.

AU - Johnson, D. H.

N1 - Funding Information: This study was coordinated by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D., Chair); participating cooperative groups included the Cancer and Leukemia Group B, the North Central Cancer Treatment Group, the Radiation Therapy Oncology Group, and the Southwest Oncology Group. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Supported in part by grants from the Public Health Service (CA23318, CA66636, CA21115, CA14958, CA49957, CA21076, CA73590, CA25224, CA21661, CA20319), the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services.

PY - 2002/9

Y1 - 2002/9

N2 - This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

AB - This study evaluates the influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group conducted a randomized prospective trial of adjuvant therapy in patients with completely resected stages II and IIIa NSCLC. A laboratory correlative study assessed the prevalence and prognostic significance of p53 and K-ras mutations. Patients were randomized to receive either radiotherapy (RT) alone or four cycles of cisplatin and VP-16 administered concurrently with radiotherapy (CRT). Median survival was 35 months for the 285 men and 41 months for the 203 women enrolled in the study (P=0.12). The relative risk (RR) of death for men vs women was 1.19 (95% confidence interval [CI], 0.95-1.49). Median survival of the 147 men and 95 women randomized to the RT arm was 39 months each (P=0.35). Median survival of the 138 men and 108 women randomized to the CRT arm was 30 and 42 months, respectively (P=0.18). Disease recurrence patterns were similar between the genders. Univariate and multivariate analyses demonstrated improved survival for women with tumors of non-squamous histology (P<0.01). The distribution of p53 and K-ras mutations was similar between the genders and had no influence on survival. Gender does not influence survival following adjuvant RT or CRT administered to patients with completely resected stages II and IIIa NSCLC. However, women with non-squamous histology have increased survival when compared to men.

KW - Adjuvant therapy

KW - Gender

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0036754178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036754178&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(02)00103-4

DO - 10.1016/S0169-5002(02)00103-4

M3 - Article

C2 - 12234700

AN - SCOPUS:0036754178

SN - 0169-5002

VL - 37

SP - 303

EP - 309

JO - Lung Cancer

JF - Lung Cancer

IS - 3

ER -

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this